Top

Published in:

01-02-2007

Reduced Incidence of Nodal Micrometastasis after Major Response to Neoadjuvant Chemoradiation in Locally Advanced Esophageal Cancer

Authors: Klaus L. Prenzel, MD, Alexandra König, MD, Paul M. Schneider, MD, Christian Schnickmann, MD, Stephan E. Baldus, MD, Wolfgang Schröder, MD, Elfriede Bollschweiler, MD, Hans P. Dienes, MD, Rolf P. Mueller, MD, Jakob R. Izbicki, MD, Arnulf H. Hölscher, MD

Published in: Annals of Surgical Oncology | Issue 2/2007

Abstract

Background

Neoadjuvant treatment modalities for esophageal cancer were developed to improve local tumor control as well as to reduce lymph node metastases and distant metastases in patients with locally advanced esophageal cancer. The influence on nodal micrometastasis has not yet been evaluated.

Methods

This study includes 52 patients with localized (cT2-4, Nx, M0) esophageal cancers (21 adenocarcinomas, 31 squamous cell cancers) who received neoadjuvant chemoradiation (36Gy, 5-FU, cisplatin) followed by transthoracic en bloc esophagectomy with two field lymphadenectomy. The extent of histomorphologic regression was categorized into major (< 10%) and minor response (>10% vital residual tumor cells) as recently reported. A total of 1186 lymph nodes were diagnosed as negative for metastases by routine histopathological analysis and were further examined for the presence of isolated tumor cells with the monoclonal anti-epithelial antibody AE1/AE3.

Results

Twenty-two tumors (42.3%) showed a major histopathologic response whereas in 30 tumors (57.7%) only a minor response was present.

Of 32 patients with a pN0 category, major response was present in 19 (59.4%) tumors, whereas 13 (40.6%) tumors showed minor response. Nine (69%) out of 13 patients with minor response had AE1/AE3-positive cells in their lymph nodes, whereas only four (21%) out of 19 pN0-patients with major response showed nodal micrometastasis (P = 0.013, χ²-test).

Conclusions

If tumors show a major histomorphologic response following neoadjuvant chemoradiation, the presence of nodal micrometastasis is significantly reduced compared to those with minor response.

Refaely Y, Krasna MJ. Multimodality therapy for esophageal cancer. Surg Clin North Am 2002; 82(4):729–46PubMedCrossRef

Izbicki JR, Hosch SB, Pichlmeier U, et al. Prognostic value of immunohistochemically identifiable tumor cells in lymph nodes of patients with completely resected esophageal cancer. N Engl J Med 1997; 337(17):1188–94PubMedCrossRef

Hosch SB, Stoecklein NH, Pichlmeier U, et al. Esophageal cancer: the mode of lymphatic tumor cell spread and its prognostic significance. J Clin Oncol 2001; 19(7):1970–5PubMed

Urba SG, Orringer MB, Turrisi A, et al. Randomized trial of preoperative chemoradiation versus surgery alone in patients with locoregional esophageal carcinoma. J Clin Oncol 2001; 19(2):305–13PubMed

Walsh TN, Noonan N, Hollywood D, et al. A comparison of multimodal therapy and surgery for esophageal adenocarcinoma. N Engl J Med 1996; 335(7):462–7PubMedCrossRef

Group MRCOCW. Surgical resection with or without preoperative chemotherapy in oesophageal cancer: a randomised controlled trial. Lancet 2002; 359(9319):1727–33CrossRef

Schneider PM, Baldus SE, Metzger R, et al. Histomorphologic tumor regression and lymph node metastases determine prognosis following neoadjuvant radiochemotherapy for esophageal cancer: implications for response classification. Ann Surg 2005; 242(5):684–92PubMedCrossRef

Scheunemann P, Izbicki JR, Pantel K. Tumorigenic potential of apparently tumor-free lymph nodes. N Engl J Med 1999; 340(21):1687PubMedCrossRef

Bollschweiler E, Schroder W, Holscher AH, Siewert JR. Preoperative risk analysis in patients with adenocarcinoma or squamous cell carcinoma of the oesophagus. Br J Surg 2000; 87(8):1106–10PubMedCrossRef

10.

Sobin LH, Wittekind C. International Union Against Cancer (UICC) TNM Classification Of Malignant Tumors. 5 ed. New York: Wiley, 1997

11.

Holscher AH, Schroder W, Bollschweiler E, et al. How safe is high intrathoracic esophagogastrostomy? Chirurg 2003; 74(8):726–733PubMedCrossRef

12.

Schroder W, Monig SP, Baldus SE, et al. Frequency of nodal metastases to the upper mediastinum in Barrett’s cancer. Ann Surg Oncol 2002; 9(8):807–11PubMed

13.

Japanese Gastric Cancer A. Japanese Classification of Gastric Carcinoma - 2nd English Edition. Gastric Cancer 1998; 1(1):10–24CrossRef

14.

Baldus SE, Monig SP, Schroder W, et al. Regression of oesophageal carcinomas after neoadjuvant radiochemotherapy: criteria of the histopathological evaluation. Pathologe 2004; 25(6):421–427PubMedCrossRef

15.

Darnton SJ, Allen SM, Edwards CW, Matthews HR. Histopathological findings in oesophageal carcinoma with and without preoperative chemotherapy. J Clin Pathol 1993; 46(1):51–5PubMedCrossRef

16.

Miller AB, Hoogstraten B, Staquet M, Winkler A. Reporting results of cancer treatment. Cancer 1981; 47(1):207–14PubMedCrossRef

17.

Baldus SE, Zirbes TK, Engel S, et al. Correlation of the immunohistochemical reactivity of mucin peptide cores MUC1 and MUC2 with the histopathological subtype and prognosis of gastric carcinomas. Int J Cancer 1998; 79(2):133–8PubMedCrossRef

18.

Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958; 53:187–220CrossRef

19.

Mantel N. Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep 1966; 50(3):163–70PubMed

20.

Jiao X, Krasna MJ. Clinical significance of micrometastasis in Lung and esophagela cancer: a new paradigm in thoracic oncology. Ann Thorac Surg 2002; 74:278–284PubMedCrossRef

21.

Ancona E, Ruol A, Santi S, et al. Only pathologic complete response to neoadjuvant chemotherapy improves significantly the long term survival of patients with resectable esophageal squamous cell carcinoma: final report of a randomized, controlled trial of preoperative chemotherapy versus surgery alone. Cancer 2001; 91(11):2165–74PubMedCrossRef

22.

Urschel JD, Vasan H. A meta-analysis of randomized controlled trials that compared neoadjuvant chemoradiation and surgery to surgery alone for resectable esophageal cancer. Am J Surg 2003; 185(6):538–43PubMedCrossRef

23.

Kaklamanos IG, Walker GR, Ferry K, et al. Neoadjuvant treatment for resectable cancer of the esophagus and the gastroesophageal junction: a meta-analysis of randomized clinical trials. Ann Surg Oncol 2003; 10(7):754–61PubMedCrossRef

24.

Natsugoe S, Matsumoto M, Nakshima S, et al. Effect of neoadjuvant chemotherapy for lymph node micrometastasis and tumor cell microinvolvement in patients with esophageal carcinoma. Cancer Letters 2000; 159:119–125PubMedCrossRef

25.

Pantel K, Schlimok G, Braun S. Differential expression of proliferation-associated molecules in individual micrometastatic carcinoma cells. N Engl J Med 1993; 85:1419–1424

26.

Braun S, Kentenich C, Janni W, et al. Lack of effect of adjuvant chemotherapy on the elimination of single dormant tumor cells in bone marrow of high-risk breast cancer patients. J Clin Oncol 2000; 18:80–86PubMed

27.

Kienle P, Koch M, Autschbach F, et al. Decreased detection rate of disseminated tumor cells of rectal cancer patients after preoperative chemoradiation: a first step towards a molecular surrogate marker for neoadjuvant treatment in colorectal cancer. Ann Surg 2003; 238(3):324–331PubMed

28.

Koshy M, Esiashvilli N, Landry JC, et al. Multiple managemet modalities in esophageal cancer: combined modality management approaches. The Oncologist 2004; 9:147–159PubMedCrossRef

Title: Reduced Incidence of Nodal Micrometastasis after Major Response to Neoadjuvant Chemoradiation in Locally Advanced Esophageal Cancer
Authors: Klaus L. Prenzel, MD
Alexandra König, MD
Paul M. Schneider, MD
Christian Schnickmann, MD
Stephan E. Baldus, MD
Wolfgang Schröder, MD
Elfriede Bollschweiler, MD
Hans P. Dienes, MD
Rolf P. Mueller, MD
Jakob R. Izbicki, MD
Arnulf H. Hölscher, MD
Publication date: 01-02-2007
Publisher: Springer-Verlag
Published in: Annals of Surgical Oncology / Issue 2/2007
Print ISSN: 1068-9265
Electronic ISSN: 1534-4681
DOI: https://doi.org/10.1245/s10434-006-9141-6

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Reduced Incidence of Nodal Micrometastasis after Major Response to Neoadjuvant Chemoradiation in Locally Advanced Esophageal Cancer

Abstract

Background

Methods

Results

Conclusions

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 2/2007

Lymphadenectomy for Adenocarcinoma of the Gastroesophageal Junction (GEJ): Impact of Adequate Staging on Outcome

Influence of Overweight on Surgical Complications for Gastric Cancer: Results From a Randomized Control Trial Comparing D2 and Extended Para-aortic D3 Lymphadenectomy (JCOG9501)

Prognostic Factors in Papillary and Follicular Thyroid Carcinoma: Their Implications for Cancer Staging

Clinicopathological Features and Prognosis in Resectable Synchronous and Metachronous Colorectal Liver Metastasis

Image Guidance during Abdominal Exploration for Recurrent Colorectal Cancer

Host Cytokine Genotype is Related to Adverse Prognosis and Systemic Inflammation in Gastro-Oesophageal Cancer